Condition: TNBC - Triple-Negative Breast Cancer · Sponsor: Huihua Xiong
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
This description comes directly from the study's public registry record.
Huihua Xiong, PI · 027-83663405 · xionghuihua@hotmail.com
Tengfei Chao, Sub-I · 027-83663409 · turnface@126.com
Always discuss trial participation with your own doctor first.
| Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06125080